Ruikang Pharmaceutical: Announcement on the provision of guarantees by wholly-owned subsidiaries to listed companies
Securities code: 002589 Securities abbreviation: Ruikang Pharmaceutical Announcement number: 2026-004 Ruikang Pharmaceutical Group Co., Ltd.
Announcement on Wholly-Owned Subsidiaries Provide Guarantees for Listed Companies
1. Overview of guarantee situation
Ruikang Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Ruikang Pharmaceutical") held the ninth meeting of the fifth board of directors on October 30, 2024, and reviewed and approved the "Proposal on the Company and its wholly-owned and controlled subsidiaries to apply for adjustment of comprehensive credit lines from relevant domestic and overseas financial institutions", and agreed that the company and its wholly-owned and controlled subsidiaries would apply for a comprehensive credit line of no more than 5 billion yuan from relevant domestic and overseas banks. For details, please refer to the "Announcement on the Resolution of the Ninth Meeting of the Fifth Board of Directors" (announcement number: 2024-032) disclosed by Ruikang Pharmaceutical in China Securities Journal, Securities Times, Securities Daily, Shanghai Securities News and cninfo.com (http://www.cninfo.com.cn) on October 31, 2024.
According to Ruikang Pharmaceutical's business and development needs, it has applied for a comprehensive credit line of no more than RMB 924 million in total from the financial institutions in the following list. Ruikang Pharmaceutical (Shandong) Co., Ltd. (hereinafter referred to as "Ruikang Shandong") and Shandong Lekang Jinyue Industrial Co., Ltd. (hereinafter referred to as "Lekang Jinyue"), Ruikang Pharmaceutical's wholly-owned subsidiaries, provide joint liability guarantees for the company's above-mentioned financing matters.
Credit line
Company name Financial institution name Term
(RMB: 10,000 yuan)
Ruikang Shandong, Industrial Bank Co., Ltd. cigarettes
92,400.00 No more than 3 years Lekang Jinyue Taiwan Branch
According to relevant regulations such as the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1 - Standardized Operation of Main Board Listed Companies", the above guarantee matters have gone through the internal approval procedures of Ruikang Shandong and Lekang Jinyue and do not need to be submitted to Ruikang Pharmaceutical's board of directors and shareholders' meeting for review.
2. Basic information of the guaranteed person
Name of the guaranteed party: Ruikang Pharmaceutical Group Co., Ltd.
Unified social credit code: 91370000766690447B
Type: other joint stock limited company (listed)
Date of establishment: September 21, 2004
Business period: September 21, 2004 to no fixed period
Address: Building 13, No. 103, Fengming Road, Zhifu District, Yantai City
Legal representative: Han Xu
Registered capital: RMB 1,504,710,471
Business scope: General items: Operation of Class II non-drug precursor chemicals; Operation of Class III non-drug precursor chemicals; sales of chemical products (excluding licensed chemical products); purchase of Chinese herbal medicines; purchase and sale of real estate Chinese herbal medicines (excluding Chinese medicine pieces); purchase of primary agricultural products; sales of agricultural and sideline products; preliminary processing of edible agricultural products; wholesale of edible agricultural products; sales of Class I medical devices; Class II medical products Sales of medical equipment; leasing of Class I medical equipment; leasing of Class II medical equipment; food sales (only sales of prepackaged food); sales of infant formula milk powder and other infant formula foods; sales of health food (prepackaged); sales of formula foods for special medical purposes; Internet sales of food (only sales of prepackaged food); sales of office supplies; sales of office equipment consumables; wholesale of daily necessities; wholesale of cosmetics Development; sales of disinfectants (excluding hazardous chemicals); sales of teaching models and teaching aids; sales of special teaching instruments; sales of glass instruments; sales of maternal and infant products; software development; information system integration services; sales of electronic products; retail of computer software, hardware and auxiliary equipment; wholesale of computer software, hardware and auxiliary equipment; repair of special equipment; maintenance of electronic and mechanical equipment (excluding special equipment); packaging materials and Sales of products; sales of sanitary products and disposable medical supplies; sales of special labor protection products; business training (excluding education training, vocational skills training and other training that require a license); technical services, technology development, technical consultation, technology exchange, technology transfer, technology promotion; general cargo warehousing services (excluding hazardous chemicals and other items that require license approval); technology import and export; goods import and export. (Except for items that require approval according to law, business activities can be carried out independently with a business license in accordance with the law) Licensed items: wholesale of medicines; sales of pharmaceutical precursor chemicals; import and export of medicines; pharmaceutical Internet information services; operation of Class I non-drug precursor chemicals; operation of Class III medical devices; rental of Class III medical equipment; sales of disinfection equipment; sales of optical instruments; Internet information services of medical devices; decoction services of traditional Chinese medicine slices; road cargo transportation (excluding dangerous goods); urban distribution and transportation services (excluding dangerous goods); road transportation of dangerous goods. (Projects that require approval according to law can only be carried out with the approval of relevant departments. Specific business projects shall be subject to the approval documents or licenses of relevant departments)
Equity structure and related relationships: Ruikang Shandong and Lekang Jinyue are wholly-owned subsidiaries of the company. Ruikang Pharmaceutical holds 100% equity of Ruikang Shandong and Lekang Jinyue.
The financial data of Ruikang Pharmaceutical in the past year are as follows:
Unit: 10,000 yuan January-September 2025 2024
Project
(Unaudited) (Audited)
Total assets 1,532,895.4 1,601,232
Total liabilities 987,477.4 1,031,770.18
Net assets 545,418.01 569,461.82
Operating income 540,653.36 796,634.56
Total profit 454.5 4,156.88
Net profit 2,700.41 4,101.78
Contingencies: None
The company is not the party subject to breach of trust.
3. The impact of the wholly-owned subsidiary’s provision of guarantee for Ruikang Pharmaceutical on the listed company
The above-mentioned guarantee matters have undergone corresponding internal approval procedures. The wholly-owned subsidiary's guarantee for Ruikang Pharmaceutical has controllable risks, which is conducive to improving the listed company's financing capabilities, ensuring Ruikang Pharmaceutical's normal operating capital needs, meeting its business development needs, and in line with the overall interests. This guarantee complies with relevant regulations, the decision-making process is legal and effective, and there is no harm to the interests of the listed company and all shareholders, especially small and medium-sized shareholders.
4. Cumulative number of external guarantees and number of overdue guarantees
As of the disclosure date of this announcement, Ruikang Pharmaceutical's actual guarantee balance is 563.513 million yuan, accounting for 9.90% of its latest audited net assets attributable to the parent company. Ruikang Pharmaceutical and its subsidiaries have no overdue external guarantees, guarantees involved in litigation, or losses due to the failure of the guarantee judgment.
5. Documents for reference
Decision of shareholders of Ruikang Pharmaceutical (Shandong) Co., Ltd.;
Decision of shareholders of Shandong Lekang Jinyue Industrial Co., Ltd.;
Announcement is hereby made.
Board of Directors of Ruikang Pharmaceutical Group Co., Ltd.
April 11, 2026